NCT01510119View on ClinicalTrials.gov

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 4, 2016

Study Completion Date

January 5, 2017

Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Hydroxychloroquine

DRUG

RAD001

Trial Locations (3)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Unknown

University of Medicine and Dentistry of New Jersey, New Brunswick

University of Pittsburgh, Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01510119 - Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter